QRG Capital Management Inc. Acquires 18,251 Shares of Smith & Nephew SNATS, Inc. $SNN

QRG Capital Management Inc. lifted its holdings in Smith & Nephew SNATS, Inc. (NYSE:SNN) by 29.4% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 80,311 shares of the medical equipment provider’s stock after purchasing an additional 18,251 shares during the quarter. QRG Capital Management Inc.’s holdings in Smith & Nephew SNATS were worth $2,552,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently modified their holdings of SNN. River Road Asset Management LLC raised its position in Smith & Nephew SNATS by 13.8% in the 4th quarter. River Road Asset Management LLC now owns 3,169,644 shares of the medical equipment provider’s stock worth $103,996,000 after buying an additional 384,926 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Smith & Nephew SNATS by 5.2% in the fourth quarter. Goldman Sachs Group Inc. now owns 2,053,726 shares of the medical equipment provider’s stock worth $67,383,000 after acquiring an additional 100,697 shares during the period. Bank of America Corp DE raised its holdings in shares of Smith & Nephew SNATS by 139.9% during the third quarter. Bank of America Corp DE now owns 987,274 shares of the medical equipment provider’s stock valued at $35,828,000 after purchasing an additional 575,666 shares during the last quarter. Todd Asset Management LLC lifted its position in Smith & Nephew SNATS by 30.2% during the fourth quarter. Todd Asset Management LLC now owns 944,578 shares of the medical equipment provider’s stock valued at $30,992,000 after purchasing an additional 219,348 shares during the period. Finally, BNP Paribas Financial Markets lifted its position in Smith & Nephew SNATS by 45.5% during the third quarter. BNP Paribas Financial Markets now owns 937,943 shares of the medical equipment provider’s stock valued at $34,038,000 after purchasing an additional 293,418 shares during the period. 25.64% of the stock is owned by hedge funds and other institutional investors.

Smith & Nephew SNATS Price Performance

Shares of NYSE:SNN traded up $0.26 during midday trading on Tuesday, hitting $30.81. The company had a trading volume of 150,580 shares, compared to its average volume of 1,075,069. The company has a current ratio of 2.57, a quick ratio of 1.25 and a debt-to-equity ratio of 0.60. Smith & Nephew SNATS, Inc. has a 12-month low of $28.56 and a 12-month high of $38.79. The company has a fifty day moving average of $30.30 and a two-hundred day moving average of $32.51.

Analysts Set New Price Targets

A number of equities research analysts have commented on SNN shares. Weiss Ratings downgraded shares of Smith & Nephew SNATS from a “hold (c+)” rating to a “hold (c)” rating in a research report on Thursday, June 11th. The Goldman Sachs Group restated a “buy” rating on shares of Smith & Nephew SNATS in a research note on Monday, May 25th. Sanford C. Bernstein set a $31.85 price objective on Smith & Nephew SNATS in a report on Monday, May 11th. Canaccord Genuity Group lowered their target price on Smith & Nephew SNATS from $32.00 to $30.00 and set a “hold” rating on the stock in a report on Monday, May 11th. Finally, Wall Street Zen upgraded Smith & Nephew SNATS from a “buy” rating to a “strong-buy” rating in a research note on Saturday. One research analyst has rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $30.93.

Smith & Nephew SNATS Profile

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.